Doesn't appear to me that they've gotten anything much out of the Medibrane deal. And Carroll buying those $42,000 worth of shares on the open market at .14 shows in my opinion that she expected high product sales to continue. So for whatever reason their expectations didn't come to pass. The 2015 results show what level of profitability this company can have. They really benefited from economy of scale and it can happen again. But I don't see any reason to hold it until the next 10q in February unless it can be purchased for a lot less than current levels
News 
Market Data 
Discover 
